The intricate orchestration of human reproduction depends on delicate neuroendocrine feedback loops that regulate gonadal growth, steroidogenesis, and gametogenesis. When physiological adaptations, pharmacological agents, or pathological conditions intervene to suppress these biological processes, the phenomenon is classified as an antigonadal action. Understanding how internal and external signals downregulate the gonadal axis is foundational to both reproductive endocrinology and targeted therapeutic intervention.
Antigonadal Action
1. Concise Definition
Antigonadal action refers to any physiological, pharmacological, or biochemical process that inhibits, suppresses, or counteracts the functional activity, growth, or endocrine secretion of the gonads (the testes in males and the ovaries in females). This phenomenon directly or indirectly leads to a significant decrease in gametogenesis, gonadal steroid hormone production, and secondary sexual characteristics.
In neuroendocrinology and pharmacology, antigonadal action operates either directly at the level of gonadal tissue—by disrupting receptor signaling, enzymatic pathways of steroidogenesis, or follicular and seminiferous architecture—or centrally via the hypothalamic-pituitary-gonadal (HPG axis). Central mechanisms typically involve the downregulation or antagonism of gonadotropin-releasing hormone (GnRH) and the subsequent inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the anterior pituitary gland.
The concept spans diverse clinical and biological domains, including seasonal reproductive quiescence mediated by pineal melatonin secretion, targeted hormone-suppressive therapies for reproductive cancers, chemical contraception, and environmental endocrine disruption.
2. Etymology & Linguistic Origin
The term antigonadal is a classical compound neoclassical construct derived from Greek and Latin roots. The prefix anti- originates from the Ancient Greek ἀντί (antí), signifying “against,” “opposite,” “in opposition to,” or “counteracting.” The root gonad stems from the Ancient Greek noun γονή (gonē), meaning “seed,” “offspring,” “generation,” or “that which begets,” which gave rise to modern anatomical usage through the New Latin gonas (plural gonades) in the late nineteenth century to designate primary reproductive organs.
The suffix -al is a Latin-derived adjectival formant meaning “pertaining to” or “characterized by.” The word action derives from the Latin actio (an act, performance, or judicial proceeding), originating from the supine stem of the verb agere (“to drive, lead, conduct, or do”). The compound phrase “antigonadal action” entered mid-twentieth-century physiological literature to characterize the biological behavior of pineal extracts, antigonadotropic sera, and synthetic progestins capable of arresting reproductive maturation in experimental animal models.
3. Pronunciation & Grammatical Form
Pronunciation: The standard International Phonetic Alphabet (IPA) transcription for the term is /ˌæn.ti.ɡoʊˈnæd.əl ˈæk.ʃən/ in General American English and /ˌæn.ti.ɡəʊˈnæd.əl ˈæk.ʃən/ in Received Pronunciation.
Grammatical Form and Part of Speech: “Antigonadal action” functions as a composite nominal phrase consisting of an attributive adjective (antigonadal) modifying a singular count or mass noun (action). The adjectival component antigonadal can also modify terms such as effect, potency, pathway, or compound.
Usage and Variants: In biological and biomedical literature, the term is frequently employed interchangeably with antigonadotropic action when the primary site of inhibition involves the pituitary gonadotropins, though strictly speaking, antigonadal remains a broader designation encompasssing direct peripheral ovarian and testicular suppression. Variant formulations include “antigonadal properties” and “anti-gonadal influence.”
4. Detailed Conceptual Explanation
To conceptualize antigonadal action, one must analyze the multi-tiered architecture of the reproductive endocrine system. Under baseline physiological circumstances, the hypothalamus acts as the central regulator through pulsatile release of GnRH into the hypophyseal portal system. GnRH binds to high-affinity G-protein-coupled receptors on anterior pituitary gonadotropes, triggering the synthesis and secretion of the dimeric glycoprotein hormones LH and FSH. These gonadotropins transit systemic circulation to engage cell-surface receptors on target cells within the gonads: Leydig and Sertoli cells in the testis, and theca and granulosa cells in the ovary. The resulting biological cascade drives gamete maturation and the synthesis of sex steroids, primarily testosterone, estradiol, and progesterone.
An antigonadal action disrupts this homeostatic feedback system at one or more structural nodes. At the central hypothalamic tier, antigonadal agents can abolish or desynchronize GnRH pulsatility. For instance, sustained hyperprolactinemia, high circulating levels of exogenous glucocorticoids, or elevated continuous concentrations of progesterone suppress hypothalamic kisspeptin neurons, which are the fundamental drivers of GnRH release. Deprived of rhythmic pulsatile stimulation, pituitary gonadotropes enter an unresponsive or down-regulated state, precipitating profound drops in circulating LH and FSH.
At the pituitary tier, competitive antagonism or sustained non-pulsatile agonism of GnRH receptors can trigger functional antigonadal effects. Continuous exposure to GnRH agonists initially induces an acute release of gonadotropins, known as a clinical flare, but rapidly results in the extensive internalization and desensitization of GnRH receptors. Conversely, direct GnRH antagonists competitively occupy the receptor without stimulating signal transduction, causing an immediate, flare-free collapse of gonadotropin production. In both scenarios, the downstream gonads are effectively starved of the trophic support required to maintain structural integrity and endocrine function.
Finally, antigonadal action may be exerted directly at the peripheral gonadal organ itself, entirely bypassing the pituitary gonadotropins. In this local context, compounds disrupt steroidogenic enzymes such as 17α-hydroxylase/17,20-lyase (CYP17A1), aromatase (CYP19A1), or 3β-hydroxysteroid dehydrogenase (3β-HSD). Direct toxicity to gametogenic cell lineages, disruption of the blood-testis barrier, induction of apoptosis within granulosa cell layers, or interference with gonadal microvascular perfusion all embody direct antigonadal mechanisms. Consequently, systemic gonadotropin levels may remain normal or even rise secondary to the elimination of negative feedback, yet gonadal output remains profoundly arrested.
5. Historical Development
The systematic exploration of antigonadal phenomena began during the emergence of modern endocrinology in the early twentieth century. In the 1920s and 1930s, pioneering researchers such as Bernhard Zondek and Philip Smith demonstrated that hypophysectomy resulted in rapid atrophy of the gonads, establishing that gonadal competence depends wholly on extrinsic pituitary factors. Early investigators observed that repeated injections of heterologous pituitary extracts into experimental animals eventually resulted in a progressive decline in gonadal responsiveness, a paradox that led to the discovery of neutralizing “antihormones” (later understood to be immunological antibodies against foreign proteins).
A major milestone occurred in the mid-twentieth century through the study of the mammalian pineal gland. In 1958, Aaron B. Lerner isolated melatonin from bovine pineal tissue. Subsequent decades of research led by investigators such as Russel Reiter revealed that melatonin acts as a principal mediator of antigonadal action in photoperiodic, seasonal breeding animals. Long nights and elevated sustained melatonin release caused marked testicular regression and ovarian shutdown in short-day breeders such as hamsters, providing the first physiological framework for neuroendocrine antigonadal signaling linked to circadian and circannual rhythms.
The structural elucidation of GnRH (originally termed LHRH) by Nobel laureates Andrew Schally and Roger Guillemin in 1971 catalyzed a therapeutic revolution. Although initial expectations held that GnRH would serve primarily as a pro-fertility agent, subsequent investigations demonstrated that superpotent synthetic agonists administered continuously possessed profound, paradoxically antigonadal effects. This discovery transformed the management of hormone-dependent pathologies, establishing chemical castration as a standard clinical reality and initiating decades of synthetic development that yielded pure GnRH antagonists, modern selective estrogen receptor modulators, and antiandrogenic compounds.
6. Theoretical Foundations
The study of antigonadal action is grounded in several interconnected biological and theoretical frameworks:
Negative Feedback Control Theory: Drawing directly from cybernetics and biological systems engineering, endocrine homeostasis relies on negative feedback loops. The HPG axis operates as a closed-loop servomechanism. Elevated peripheral sex steroids feed back onto the arcuate and anteroventral periventricular nuclei of the hypothalamus and the anterior pituitary to dampen kisspeptin, neurokinin B, and dynorphin (KNDy) neuronal activity, ultimately curbing LH and FSH. Antigonadal interventions often exploit this feedback control by delivering exogenous steroids to mimic an over-repleted state, shutting down endogenous axis drive.
Receptor Desensitization and Downregulation Dynamics: Cellular signaling theory explains how continuous versus pulsatile stimulation yields diametrically opposed biological outcomes. The plasma membrane-bound GnRH receptor relies on cyclic intracellular calcium fluxes and protein kinase C activation. When exposed to persistent, unyielding agonist concentration without physiological rest periods, the receptors decouple from heterotrimeric G-proteins, become phosphorylated by G-protein-coupled receptor kinases, and undergo endocytosis into lysosomes, eliminating cell responsiveness.
Life History Theory and Energy Allocation Models: Evolutionary biology interprets physiological antigonadal actions as adaptive resource-reallocation strategies. Reproduction requires massive metabolic investments. Under conditions of environmental stress, nutritional deprivation, severe infection, or unfavorable seasonal shifts, organisms downregulate gonadal function through neuroendocrine adaptations. Elevated corticotropin-releasing hormone (CRH) and central glucocorticoids exert an evolutionarily conserved antigonadal suppression, preserving energy reserves for immediate somatic survival rather than reproductive investment.
7. Key Components, Types & Dimensions
Antigonadal mechanisms can be categorized based on their site of origin, physiological nature, and clinical intent:
- Central (Neuroendocrine) Antigonadal Actions: Suppression initiated at or above the pituitary gland. Mechanisms include inhibition of hypothalamic GnRH secretion via elevated melatonin, prolactin, or stress hormones, as well as pharmaceutical GnRH receptor downregulation or antagonism.
- Peripheral (Direct Gonadal) Antigonadal Actions: Pathophysiological or targeted destruction or functional inhibition occurring within the testes or ovaries. This includes enzymatic inhibition of steroidogenesis (e.g., ketoconazole, aminoglutethimide), direct cytotoxicity to Sertoli or Leydig cells, and follicular atresia induced by chemotherapeutic alkylating agents.
- Physiological Antigonadal Actions: Adaptive suppression of the gonadal axis occurring as part of a normal biological lifecycle, such as prepubertal dormancy, seasonal reproductive involution in photoperiodic mammals, and lactational amenorrhea.
- Pharmacological Antigonadal Actions: Intentional, medically induced gonadal suppression via therapeutic agents, such as GnRH analogues, high-dose progestins, antiandrogens, and competitive estrogen blockers.
- Toxicological/Environmental Antigonadal Actions: Unintended gonadal disruption caused by exposure to industrial endocrine-disrupting chemicals (EDCs), including phthalates, bisphenols, pesticides, and heavy metals that impair gonadal morphology, gametogenesis, and steroid production.
8. Examples & Illustrative Cases
A classic physiological illustration of antigonadal action is observed in the Syrian hamster (Mesocricetus auratus). When exposed to photoperiods of less than 12.5 hours of light per day, the pineal gland extends its nocturnal synthesis of melatonin. This prolonged nightly melatonin elevation exerts a robust antigonadal effect, driving profound testicular regression, halting spermatogenesis, collapsing circulating testosterone to near-castrate levels, and inducing complete behavioral quiescence. Upon returning the animal to long photoperiods, pineal melatonin production contracts, releasing the HPG axis from antigonadal inhibition and restoring full reproductive competence.
In human clinical medicine, an illustrative case involves the management of advanced, metastatic prostate cancer. Because prostate adenocarcinoma cells depend heavily on androgen receptor activation for survival and proliferation, clinicians employ targeted antigonadal therapy termed androgen deprivation therapy (ADT). A patient receives continuous administration of a depot GnRH agonist, such as leuprolide acetate, or a direct GnRH antagonist, such as degarelix. Within weeks, the drug’s antigonadal action suppresses pituitary LH secretion, depriving testicular Leydig cells of trophic signals and reducing systemic testosterone levels below 20 ng/dL. This dramatic reduction depresses tumor growth and causes significant regression of metastatic lesions.
A third scenario is observed in functional hypothalamic amenorrhea (FHA) secondary to relative energy deficiency in sport (RED-S). In an elite female endurance athlete undergoing intensive physical training with insufficient caloric intake, the central nervous system perceives severe metabolic deficit. Elevated levels of systemic cortisol and adipokine dysregulation (low leptin, elevated ghrelin) act centrally on the hypothalamus to silence pulsatile GnRH discharge. This endogenous antigonadal response suppresses ovarian estrogen production, halts follicular development, and results in amenorrhea and secondary osteopenia.
9. Measurement & Assessment
Assessing antigonadal action requires evaluating both central endocrine signals and peripheral tissue responses through laboratory, imaging, and histological methodologies:
Serum Hormone Assays: The primary method for quantifying antigonadal impact involves measuring circulating endocrine markers via chemiluminescent immunoassays, radioimmunoassays, and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Critical biochemical parameters include:
- Pituitary gonadotropins: Serum LH and FSH concentrations.
- Gonadal steroids: Total and free testosterone, estradiol, and progesterone.
- Upstream and counter-regulatory markers: Serum prolactin, sex hormone-binding globulin (SHBG), inhibin B (reflecting Sertoli cell and spermatogenic reserve), and anti-Müllerian hormone (AMH, indicating ovarian follicular reserve).
Functional Endocrine Testing: Dynamic provocation tests are employed when baseline measurements are inconclusive. The GnRH stimulation test involves administering an intravenous bolus of synthetic gonadal releasing hormone followed by serial blood sampling at 15, 30, and 60 minutes. An absent or blunted LH and FSH response confirms profound pituitary downregulation, distinguishing central antigonadal actions from primary peripheral failure where gonadotropin hyperresponsiveness would otherwise occur.
Morphological and Histological Imaging: The physical consequences of antigonadal actions are quantified through high-resolution transvaginal pelvic ultrasound (assessing ovarian volume, antral follicle count, and endometrial thickness) or scrotal ultrasonography (measuring testicular volume and parenchymal echogenicity). In experimental animal studies, assessment involves quantitative histological analyses, such as calculating the Johnsen score for spermatogenesis, quantifying apoptotic Leydig or granulosa cells through TUNEL staining, and evaluating ovarian primordial follicle densities.
10. Applications & Practical Significance
The controlled application of antigonadal mechanisms represents a major pillar of contemporary clinical pharmacology, oncology, and gynecology:
Oncology: As noted in androgen deprivation therapy for prostate cancer, therapeutic antigonadal action is equally essential in female oncology. In premenopausal women presenting with hormone receptor-positive (ER+/PR+) breast cancer, ovarian function suppression (OFS) achieved via GnRH analogues significantly lowers circulating estradiol, removing the primary mitogenic driver of malignant breast tissue and substantially extending disease-free survival.
Gynecological Pathologies: Antigonadal therapy is routinely utilized to treat estrogen-dependent benign conditions. Patients suffering from severe endometriosis, adenomyosis, or symptomatic uterine leiomyomas (fibroids) are treated with GnRH agonists or oral non-peptide GnRH antagonists (e.g., elagolix, relugolix). The resulting hypoestrogenic state deprives ectopic endometrial implants of the hormonal stimuli required to proliferate, bleed, and induce inflammatory pain, leading to symptomatic relief and tissue regression.
Transgender and Gender-Affirming Medicine: In gender-affirming medical care, antigonadal actions are harnessed to suppress an individual’s endogenous secondary sexual characteristics. Transgender women frequently receive antiandrogenic agents (e.g., spironolactone, cyproterone acetate) or GnRH analogues to abolish endogenous testicular androgen synthesis. Similarly, GnRH analogues are administered to transgender adolescents at the onset of puberty (Tanner stage 2) as reversible pubertal blockers, preventing unwanted endogenous virilization or feminization and providing psychological relief and time for clinical evaluation.
Assisted Reproductive Technology (ART): Ironically, temporary antigonadal action is critical for promoting fertility during controlled ovarian stimulation protocols for in vitro fertilization (IVF). GnRH antagonists are administered to precisely suppress the endogenous pituitary LH surge, preventing premature, uncontrolled ovulation before mature oocytes can be surgically retrieved from ovarian follicles.
11. Research & Empirical Evidence
Extensive preclinical and human clinical research continues to characterize the scope and molecular pathways of antigonadal mechanisms. Seminal investigations led by Belchetz and colleagues in 1978 established that only pulsatile, rather than continuous, intravenous delivery of GnRH could restore gonadotropin secretion in hypothalamus-lesioned rhesus monkeys, demonstrating the desensitization-driven antigonadal action of constant agonist exposure. This mechanistic insight was subsequently leveraged in extensive multi-center clinical trials, including work led by Huggins (who previously established the hormonal dependence of prostate cancer) and later Schally’s team, showing the efficacy of sustained-release depot formulations of GnRH analogues in clinical oncology.
Modern investigations focus heavily on the neuroendocrine role of the KISS1 gene product, kisspeptin, and its receptor, KISS1R. Seminal work by Seminara et al. (2003) and de Roux et al. (2003) revealed that mutations disrupting kisspeptin signaling lead to profound hypogonadotropic hypogonadism. Contemporary researchers explore kisspeptin antagonists as potential next-generation antigonadal therapies capable of fine-tuning HPG axis suppression with greater precision and fewer metabolic side effects than traditional GnRH-targeted drugs.
In the arena of environmental toxicology, landmark epidemiological and toxicological studies by researchers like Shanna Swan have highlighted the unintended antigonadal actions of xenobiotics. Investigations into environmental antiandrogens, such as di-(2-ethylhexyl) phthalate (DEHP), have confirmed that fetal exposure during critical gestational windows blunts Leydig cell testosterone production, contributing to testicular dysgenesis syndrome (TDS)—characterized by increased rates of cryptorchidism, hypospadias, low sperm counts, and testicular germ cell tumors.
12. Cultural & Cross-Cultural Considerations
The perception, acceptance, and social implications of antigonadal actions vary widely across historical epochs and modern cultural landscapes. In ancient and pre-modern societies, irreversible surgical antigonadal action—castration—was institutionalized across Byzantine, Ottoman, Chinese imperial courts, and certain religious sects (such as the Skoptsy in imperial Russia) to create eunuchs for administrative, domestic, or religious roles, deliberately removing reproductive drives and familial allegiances.
In modern societies, the deployment of antigonadal pharmaceuticals intersects with diverse cultural and ethical values. The use of reversible antigonadal agents as “chemical castration” in the penal justice system for convicted sex offenders remains intensely controversial. Proponents argue it protects public safety by suppressing recidivistic paraphilic drives, whereas critics, bioethicists, and international human rights bodies challenge its compatibility with bodily autonomy, informed consent, and protections against cruel or unusual punishment.
Furthermore, cultural perceptions of masculinity and femininity profoundly shape patient adherence to therapeutic antigonadal interventions. In many cultures, the physical side effects of antigonadal treatments—such as erectile dysfunction, testicular atrophy, loss of muscular mass, hot flashes, and gynecomastia in men, or vasomotor instability, vaginal dryness, and emotional changes in women—carry heavy social stigmas. Patients may interpret these side effects as an existential compromise of their gender identity, leading to psychological distress, non-compliance with oncological therapies, or resistance to medical guidelines. Effective clinical communication across varied cultural backgrounds requires nuanced cultural competency to frame these antigonadal effects within appropriate therapeutic boundaries.
13. Criticisms, Debates & Limitations
Despite its profound therapeutic utility, antigonadal action carries major physiological, psychological, and pharmacological limitations:
Somatic Morbidity of Long-Term Hypogonadism: Prolonged, deep suppression of the gonadal axis mimics premature surgical menopause or severe hypogonadism. Estrogen and testosterone are essential homeostatic hormones that regulate bone remodeling, lipid profiles, cardiovascular integrity, and cognitive function. Extended antigonadal therapy dramatically accelerates bone mineral density loss, precipitating severe osteoporosis and fragility fractures. Additionally, it increases the risk of metabolic syndrome, insulin resistance, adverse cardiovascular events, and neurocognitive decline.
Psychological and Quality-of-Life Burden: The abrupt cessation of sex steroid signaling is associated with adverse psychiatric outcomes. Patients frequently report fatigue, severe depressive episodes, anhedonia, sleep disturbances, irritability, and a near-total collapse of libido. In oncological settings, these side effects can erode quality of life to such an extent that patients may discontinue life-prolonging treatments.
Reversibility and Refractory Recovery: While pharmacological antigonadal action is conventionally conceptualized as fully reversible, real-world clinical data demonstrate significant heterogeneity in axis recovery. Following extended administration of depot GnRH analogues or high-dose synthetic progestins, hypothalamic-pituitary-gonadal reactivation may be significantly delayed. In some older or vulnerable individuals, the axis may fail to regain baseline capacity, leading to permanent secondary hypogonadism.
14. Related Terms & Distinctions
To prevent diagnostic and pharmacological ambiguity, antigonadal action must be distinguished from several closely related terms:
- Antigonadal vs. Antigonadotropic: Antigonadotropic refers strictly to actions that suppress the synthesis, release, or bioactivity of pituitary gonadotropins (LH and FSH). While every central antigonadotropic effect produces an antigonadal outcome, antigonadal is broader, also including direct actions on the ovaries or testes independent of gonadotropins.
- Antigonadal vs. Antiandrogenic: Antiandrogenic refers specifically to blocking the action or synthesis of androgens. An antiandrogen (such as enzalutamide or flutamide) acts primarily at the level of the androgen receptor, blocking testosterone and dihydrotestosterone without necessarily turning off the gonads; in fact, pure androgen receptor antagonists can cause a compensatory rise in gonadotropin and testosterone secretion due to hypothalamic disinhibition.
- Antigonadal vs. Hypogonadism: Hypogonadism is a clinical and biochemical diagnosis reflecting deficient gonadal functional output. Antigonadal action refers to the mechanism, process, or agent that induces or causes that hypogonadal state.
- Antigonadal vs. Contraceptive: While antigonadal actions can be employed for contraceptive purposes (e.g., combined hormonal contraceptives suppressing ovulation), not all contraceptives rely on antigonadal mechanisms. For instance, copper intrauterine devices, barrier methods, and tubal ligation achieve contraception without altering gonadal steroidogenesis or gametogenic endocrine function.
15. Summary / Key Takeaways
Antigonadal action represents the physiological, pharmacological, or toxicological downregulation of gonadal activity, resulting in arrested gametogenesis and suppressed production of sex steroid hormones. Mediated centrally via disruption of hypothalamic kisspeptin and GnRH pulsatility or pituitary gonadotropin release, or peripherally through direct enzymatic and cellular inhibition within testicular and ovarian tissue, this phenomenon plays an essential role across multiple biological domains.
Clinically, antigonadal interventions are critical tools in modern medicine, providing effective treatment strategies for hormone-sensitive malignancies (prostate and breast cancers), common gynecological disorders (endometriosis, uterine fibroids), and gender-affirming medical therapies. However, because sex steroids are vital for multi-system homeostasis, therapeutic antigonadal suppression requires careful clinical balance to minimize adverse systemic consequences, including accelerated bone loss, cardiovascular risks, metabolic dysregulation, and psychological burdens.
In summary, antigonadal action highlights the delicate balance of the endocrine system, illustrating how targeted neuroendocrine suppression can serve as both a natural survival adaptation and a potent therapeutic tool in clinical medicine.
References
- Belchetz, P. E., Plant, T. M., Nakai, Y., Keogh, E. J., & Knobil, E. (1978). Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science, 202(4368), 631–633. https://doi.org/10.1126/science.100883
- Lerner, A. B., Case, J. D., Takahashi, Y., Lee, T. H., & Mori, W. (1958). Isolation of melatonin, the pineal gland factor that lightens melanocytes. Journal of the American Chemical Society, 80(10), 2587. https://doi.org/10.1021/ja01543a060
- Reiter, R. J. (1980). The pineal and its hormones in the control of reproduction in mammals. Endocrine Reviews, 1(2), 109–131. https://doi.org/10.1210/edrv-1-2-109
- Schally, A. V., Arimura, A., Baba, Y., Nair, R. M., Matsuo, H., Redding, T. W., Debeljuk, L., & White, W. F. (1971). Isolation and properties of the FSH and LH-releasing hormone. Biochemical and Biophysical Research Communications, 43(2), 393–399. https://doi.org/10.1016/0006-291x(71)90766-3
- Seminara, S. B., Messager, S., Chatzidaki, E. E., Thresher, R. R., Acierno, J. S., Shagoury, J. K., Bo-Abbas, Y., Kuohung, W., Schwinof, K. M., Hendrick, A. G., Zahn, D., Dixon, J., Kaiser, U. B., Slaugenhaupt, S. A., Gusella, J. F., O’Rahilly, S., Carlton, M. B., Crowley, W. F., Jr., Aparicio, S. A., & Colledge, W. H. (2003). The GPR54 gene as a regulator of puberty. New England Journal of Medicine, 349(17), 1614–1627. https://doi.org/10.1056/NEJMoa035322